ABOS Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

a month ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

a month ago - By: Benzinga

Preview: Acumen Pharmaceuticals's Earnings

4 months ago - By: Benzinga

Acumen Pharmaceuticals's Earnings: A Preview

a month ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease

a month ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

a month ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

a month ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

a month ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

a month ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

a month ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

a month ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

4 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

5 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

5 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

5 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

5 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

5 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

5 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

7 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

9 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

9 months ago - By: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

9 months ago - By: Climb Bio, Inc. - Mentions: CLYM LENZ SLDB VERV

ACUMEN PHARMACEUTICALS INC (ABOS) Stock News

ABOS Latest News, Press Relases and Analysis

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Preview: Acumen Pharmaceuticals's Earnings

Acumen Pharmaceuticals's Earnings: A Preview

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors